[Pyr11]-Amyloid β-Protein (Human,11-40) (0.5 mg Vial)

Product overview
Catalog Number
PPH08-0913
Sequence
Pyr-Val-His-His-Gln-Lys-Leu-Val-Phe-Phe-Ala-Glu-Asp-Val-Gly-Ser-Asn-Lys-Gly-Ala-Ile-Ile-Gly-Leu-Met-Val-Gly-Gly-Val-Val
Target
Endogenous Truncated Amyloid β-Protein
Description
Peptide to [Pyr11]-Beta-Amyloid-Protein (11-40) A hallmark of Alzheimer's disease (AD) is the presence of beta-Amyloid in plaques in the brains of patients. N-terminally truncated pyroglutamate-modified beta-Amyloid forms such as Aß(3-40) and Aß (11- 40) have been described as major compounds in the senile plaques. Pyro-Glu modified beta-Amyloid forms are more resistant to degradation, show higher toxicity and have increased aggregation propensity compared to non-modified beta-Amyloid. 192377-94-9. C143H226N38O39S. MW 3133.71. Endogenous Truncated Amyloid β-Protein. (Trifluoroacetate Form)
Category
Catalog peptides, Biologically Active Peptides
Product Properties
Quantity

1mg
Storage

Shipped at 4°C. Store at -20°C for one year.
Purity

> 95%
Source

Synthetic
Forma appearance

Lyophilized powder
Price

€130,00
  • For research use only
  • Not for use in diagnostic procedures

€130,00 Tax excluded
Contact us to request price here
Register to buy peptides
Contact us